TG Therapeutics focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.Read more
Chairman & CEO
Michael S. Weiss
TG Therapeutics's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 13.3B. Over the last four quarters, TG Therapeutics's revenue has grown by 5242.1%. Specifically, in Q3 2021's revenue was $2M; in Q2 2021, it was $1.5M; in Q1 2021, it was $ < 1M; in Q4 2020, TG Therapeutics's revenue was $ < 1M.